Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 15Terminated 5Unknown 2Recruiting 2Withdrawn 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 43Other hematologic neoplasm 40Myeloid 8Sarcoma 3Breast 3Genitourinary 2Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 86pembrolizumab 76Specimen Handling 75enzalutamide 55Radiosurgery 55Radiotherapy 51Docetaxel 50Androgen Antagonists 47Gemcitabine 42Nivolumab 39darolutamide 37Prednisone 35enfortumab vedotin 32Abiraterone Acetate 31Cisplatin 30Biopsy 30Carboplatin 29cabozantinib 28Standard of Care 28apalutamide 27Pluvicto 26abiraterone 25Blood Specimen Collection 25Radiation 23Leuprolide 23Ipilimumab 22X-Rays 18relugolix 17Triptorelin Pamoate 17Surveys and Questionnaires 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Methotrexate × Genitourinary × Clear all
NCT04628767 2026-05-13

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
249 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT06960577 2026-04-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

AstraZeneca

Phase 3 Recruiting
150 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡